Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Jul;70(1):35–41. doi: 10.1038/bjc.1994.246

Comparative biodistributions of indium-111-labelled macrocycle chimeric B72.3 antibody conjugates in tumour-bearing mice.

A Turner 1, D J King 1, A P Farnsworth 1, S K Rhind 1, R B Pedley 1, J Boden 1, R Boden 1, T A Millican 1, K Millar 1, B Boyce 1, et al.
PMCID: PMC2033299  PMID: 8018538

Abstract

A novel 111In ligand (a C-functionalised derivative of 1,4,7-triazacyclononanetriacetic acid), termed 9N3, was covalently attached to chimeric B72.3, labelled with 111In and compared with 111In-labelled chimeric B72.3 diethylenetriaminepentaacetic acid (DTPA) cyclic anhydride conjugate (cDTPA) and a C-linked derivative of DTPA (CT-DTPA) in athymic mice bearing human colon carcinoma xenografts. Significant differences in biodistribution were observed between 9N3 and cDTPA conjugates especially in the tumour uptake and blood, liver, femur and colon levels at 24, 48 and 144 h. Significantly higher tumour uptake was observed for 111In-cB72.3-9N3 compared with 111In-cB72.3-cDTPA at all time points. Radiolocalisation (RI) indices increased with time for the 9N3 conjugate but remained constant for the cDTPA conjugate. The biodistribution of 111In-labelled cB72.3-CT-DTPA was similar to that of 111In-labelled cB72.3-9N3 except for elevated kidney levels. A 12N4 macrocycle (a C-functionalised derivative of 1,4,7,10-tetraazacyclododecanetetraacetic acid) was also tested for its ability to chelate 111In and its biodistribution examined. Labelled conjugates with this macrocycle were more difficult to prepare in a stable form but gave a very similar biodistribution to the 9N3 macrocycle conjugate. Macrocycle-antibody conjugates of this type offer considerable promise for tumour imaging in patients.

Full text

PDF
35

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adair J. R. Engineering antibodies for therapy. Immunol Rev. 1992 Dec;130:5–40. doi: 10.1111/j.1600-065x.1992.tb01519.x. [DOI] [PubMed] [Google Scholar]
  2. Angal S., King D. J., Bodmer M. W., Turner A., Lawson A. D., Roberts G., Pedley B., Adair J. R. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol. 1993 Jan;30(1):105–108. doi: 10.1016/0161-5890(93)90432-b. [DOI] [PubMed] [Google Scholar]
  3. Brown B. A., Comeau R. D., Jones P. L., Liberatore F. A., Neacy W. P., Sands H., Gallagher B. M. Pharmacokinetics of the monoclonal antibody B72.3 and its fragments labeled with either 125I or 111In. Cancer Res. 1987 Feb 15;47(4):1149–1154. [PubMed] [Google Scholar]
  4. Colcher D., Keenan A. M., Larson S. M., Schlom J. Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. Cancer Res. 1984 Dec;44(12 Pt 1):5744–5751. [PubMed] [Google Scholar]
  5. Colcher D., Milenic D., Roselli M., Raubitschek A., Yarranton G., King D., Adair J., Whittle N., Bodmer M., Schlom J. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res. 1989 Apr 1;49(7):1738–1745. [PubMed] [Google Scholar]
  6. Davidson B. R., Babich J., Young H., Waddington W., Clarke G., Short M., Boulos P., Styles J., Dean C. The effect of circulating antigen and radiolabel stability on the biodistribution of an indium labelled antibody. Br J Cancer. 1991 Nov;64(5):850–856. doi: 10.1038/bjc.1991.412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Deshpande S. V., Subramanian R., McCall M. J., DeNardo S. J., DeNardo G. L., Meares C. F. Metabolism of indium chelates attached to monoclonal antibody: minimal transchelation of indium from benzyl-EDTA chelate in vivo. J Nucl Med. 1990 Feb;31(2):218–224. [PubMed] [Google Scholar]
  8. Divgi C. R., McDermott K., Johnson D. K., Schnobrich K. E., Finn R. D., Cohen A. M., Larson S. M. Detection of hepatic metastases from colorectal carcinoma using indium-111 (111In) labeled monoclonal antibody (mAb): MSKCC experience with mAb 111In-C110. Int J Rad Appl Instrum B. 1991;18(7):705–710. doi: 10.1016/0883-2897(91)90008-9. [DOI] [PubMed] [Google Scholar]
  9. Esteban J. M., Schlom J., Gansow O. A., Atcher R. W., Brechbiel M. W., Simpson D. E., Colcher D. New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. J Nucl Med. 1987 May;28(5):861–870. [PubMed] [Google Scholar]
  10. Goldenberg D. M., Wlodkowski T. J., Sharkey R. M., Silberstein E. B., Serafini A. N., Garty I. I., Van Heertum R. L., Higginbotham-Ford E. A., Kotler J. A., Balasubramanian N. Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. J Nucl Med. 1993 Jan;34(1):61–70. [PubMed] [Google Scholar]
  11. Granowska M., Mather S. J., Britton K. E. Diagnostic evaluation of 111In and 99mTc radiolabelled monoclonal antibodies in ovarian and colorectal cancer: correlations with surgery. Int J Rad Appl Instrum B. 1991;18(4):413–424. doi: 10.1016/0883-2897(91)90069-w. [DOI] [PubMed] [Google Scholar]
  12. Hird V., Verhoeyen M., Badley R. A., Price D., Snook D., Kosmas C., Gooden C., Bamias A., Meares C., Lavender J. P. Tumour localisation with a radioactively labelled reshaped human monoclonal antibody. Br J Cancer. 1991 Nov;64(5):911–914. doi: 10.1038/bjc.1991.425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hnatowich D. J., Childs R. L., Lanteigne D., Najafi A. The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method. J Immunol Methods. 1983 Dec 16;65(1-2):147–157. doi: 10.1016/0022-1759(83)90311-3. [DOI] [PubMed] [Google Scholar]
  14. Hnatowich D. J., Griffin T. W., Kosciuczyk C., Rusckowski M., Childs R. L., Mattis J. A., Shealy D., Doherty P. W. Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients. J Nucl Med. 1985 Aug;26(8):849–858. [PubMed] [Google Scholar]
  15. Khazaeli M. B., Saleh M. N., Liu T. P., Meredith R. F., Wheeler R. H., Baker T. S., King D., Secher D., Allen L., Rogers K. Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res. 1991 Oct 15;51(20):5461–5466. [PubMed] [Google Scholar]
  16. Kosmas C., Snook D., Gooden C. S., Courtenay-Luck N. S., McCall M. J., Meares C. F., Epenetos A. A. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res. 1992 Feb 15;52(4):904–911. [PubMed] [Google Scholar]
  17. Lamki L. M., Buzdar A. U., Singletary S. E., Rosenblum M. G., Bhadkamkar V., Esparza L., Podoloff D. A., Zukiwski A., Hortobagyi G. N., Murray J. L. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. J Nucl Med. 1991 Jul;32(7):1326–1332. [PubMed] [Google Scholar]
  18. Lundy J., Greiner J. W., Colcher D. Development of a metastatic human colon cancer xenograft model in the nude mouse. J Surg Oncol. 1986 Apr;31(4):260–267. doi: 10.1002/jso.2930310408. [DOI] [PubMed] [Google Scholar]
  19. Lyons A., King D. J., Owens R. J., Yarranton G. T., Millican A., Whittle N. R., Adair J. R. Site-specific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Eng. 1990 Aug;3(8):703–708. doi: 10.1093/protein/3.8.703. [DOI] [PubMed] [Google Scholar]
  20. Meares C. F., McCall M. J., Reardan D. T., Goodwin D. A., Diamanti C. I., McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem. 1984 Oct;142(1):68–78. doi: 10.1016/0003-2697(84)90517-7. [DOI] [PubMed] [Google Scholar]
  21. Meares C. F., Moi M. K., Diril H., Kukis D. L., McCall M. J., Deshpande S. V., DeNardo S. J., Snook D., Epenetos A. A. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl. 1990 Jul;10:21–26. [PMC free article] [PubMed] [Google Scholar]
  22. Paik C. H., Hong J. J., Ebbert M. A., Heald S. C., Reba R. C., Eckelman W. C. Relative reactivity of DTPA, immunoreactive antibody-DTPA conjugates, and nonimmunoreactive antibody-DTPA conjugates toward indium-111. J Nucl Med. 1985 May;26(5):482–487. [PubMed] [Google Scholar]
  23. Roselli M., Schlom J., Gansow O. A., Raubitschek A., Mirzadeh S., Brechbiel M. W., Colcher D. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med. 1989 May;30(5):672–682. [PubMed] [Google Scholar]
  24. Sakahara H., Endo K., Nakashima T., Koizumi M., Ohta H., Torizuka K., Furukawa T., Ohmomo Y., Yokoyama A., Okada K. Effect of DTPA conjugation on the antigen binding activity and biodistribution of monoclonal antibodies against alpha-fetoprotein. J Nucl Med. 1985 Jul;26(7):750–755. [PubMed] [Google Scholar]
  25. Schuhmacher J., Klivényi G., Matys R., Kirchgebner H., Hauser H., Maier-Borst W., Matzku S. Uptake of indium-111 in the liver of mice following administration of indium-111-DTPA-labeled monoclonal antibodies: influence of labeling parameters, physiologic parameters, and antibody dose. J Nucl Med. 1990 Jun;31(6):1084–1093. [PubMed] [Google Scholar]
  26. Whittle N., Adair J., Lloyd C., Jenkins L., Devine J., Schlom J., Raubitschek A., Colcher D., Bodmer M. Expression in COS cells of a mouse-human chimaeric B72.3 antibody. Protein Eng. 1987 Dec;1(6):499–505. doi: 10.1093/protein/1.6.499. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES